InspireMD Receives Noncompliance Notice from NYSE American

World News: . []

TEL AVIV, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that on January 7, 2019, the Company received a letter from NYSE American LLC (“NYSE American”) stating that it is not in compliance with the continued listing standards as set forth in Part 10, Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) due to the Company’s current low selling share price.

The Company’s continued listing on the NYSE American is contingent upon the Company effecting a share consolidation or otherwise demonstrating a sustained improvement in its share price within a reasonable period of time but no later than July 7, 2019.

InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

Investor Contacts:Craig ShoreChief Financial OfficerInspireMD, Inc.888-776-6804craigs@inspiremd.com 

Jeremy FefferLifeSci Advisors, LLC212-915-2568jeremy@lifesciadvisors.com

More news and information about InspireMD, Inc.

Published By:

Globe Newswire: 21:30 GMT Friday 11th January 2019

Published: .

Search for other references to "inspiremd" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us